Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The prognostic heterogeneity in patients with BRAF V600E metastatic colorectal cancer (mCRC) remains poorly defined. Real-world data of 93 BRAF V600E mCRC patients from Sun Yat-sen University Cancer Center were evaluated using the prognostic factors affecting overall survival (OS). Treatment of metastases served as an independent prognosticator, where curative locoregional interventions (LRIs) were associated with superior clinical outcomes (adjusted hazard ratio (HR): 0.46, 95% confidence interval (CI): 0.22-0.98; = 0.044). The LRIs group showed an improved median OS of 49.4 months versus 18.3 months for the palliative treatments (PTs) group. The median OS of patients with colorectal liver metastasis (CRLM) was significantly prolonged after undergoing LRIs (42.4 vs. 23.7 months; HR: 0.11, 95% CI: 0.01-1.22; = 0.030), and patients in the LRIs plus liver-limited or lung-limited metastasis (LLM) group benefited more than those in the LRIs plus non-LLM group when compared to the PTs group (LLM from LRIs vs. PTs, HR: 0.16, 95% CI: 0.04-0.68; = 0.006. Non-LLM from LRIs vs. PTs, HR: 0.47, 95% CI: 0.21-1.05; = 0.074). In conclusion, we confirmed the positive prognostic value of LRIs in BRAF V600E mCRC, particularly in patients with CRLM or LLM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468777 | PMC |
| http://dx.doi.org/10.3390/biom11091268 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Glomangiomatosis of uncertain malignant potential: a clinicopathological and genetic analysis].
Zhonghua Bing Li Xue Za Zhi
September 2025
Department of Pathology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China.
To investigate the clinicopathological features, genetic characteristics, and differential diagnosis of glomangiomatosis with uncertain malignant potential. Two cases of glomangiomatosis with uncertain malignant potential were collected at Henan Provincial People's Hospital from 2013 and 2023. Immunohistochemistry and next generation sequencing (DNA-seq) were used to detect the related protein and gene variation.
View Article and Find Full Text PDFUltrasensitive multifunctional biosensor integrating ECL quenching and DPV enhancement for early classification of thyroid cancer via BRAF V600E and microRNA-221 detection.
Biosens Bioelectron
September 2025
College of Chemistry, Jilin Province Research Center for Engineering and Technology of Spectral Analytical Instruments, Jilin University, Qianjin Street 2699, Changchun, 130012, China. Electronic address:
Papillary thyroid carcinoma (PTC) is the most prevalent form of thyroid cancer with a high incidence among endocrine malignancies. It tends to metastasize early in lymph nodes and differs markedly from other subtypes in biological behavior, clinical management, and prognosis. Therefore, accurately distinguishing PTC from other pathological subtypes is crucial for guiding diagnosis and treatment decisions.
View Article and Find Full Text PDFMultimodal ultrasonographic and clinicopathological model for predicting high-volume lymph node metastasis in cN0 papillary thyroid carcinoma.
Front Endocrinol (Lausanne)
September 2025
Department of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Background: Given the challenge in preoperative diagnosis of high-volume lymph node metastasis (HVLNM) in clinical practice, we constructed and externally validated a comprehensive predictive model that integrated conventional ultrasound characteristics, contrast-enhanced ultrasound (CEUS) parameters, BRAFmutation, and clinicopathological data for HVLNM in clinically lymph node-negative (cN0) papillary thyroid carcinoma (PTC).
Methods: Totally, 126 clinically lymph node-negative (cN0) PTC patients who underwent subtotal or total thyroidectomy and accompanied with prophylactic cervical lymph node dissection between December 2022 and December 2024 were enrolled in this retrospective study, and an additional 47 cN0 PTC patients included for the external validation cohort. Univariate and multivariate analysis were performed to identify the independent risk factors for HVLNM, and a binary logistic regression equation and relevant nomogram was constructed to predict the risk about HVLNM.
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare diffuse lung disease that is strongly associated with cigarette smoking, with the BRAF V600E mutation identified in approximately half of all cases. In Japan, combination therapy with BRAF and MEK inhibitors has recently been approved as an alternative treatment option. We report the case of a 30-year-old woman diagnosed with BRAF V600E-mutant PLCH who was treated with dabrafenib in combination with trametinib.
View Article and Find Full Text PDFTargeting melanoma resistance: Novel oxindole and non-oxindole-based benzimidazole derivatives as potent dual inhibitors of BRAF and ABL2 kinases.
Eur J Med Chem
August 2025
Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519, Minia, Egypt.
Melanoma is one of the deadliest forms of cancer. The disease is incurable for many due to its aggressive, metastatic characteristics and its elevated resistance. Herein, we design and synthesize two series of target compounds oxindole-based (7a-h) and non-oxindole-based (8a-h) benzimidazole.
View Article and Find Full Text PDF